Postmenopausal Hormone Replacement Therapy

Nelson, Heidi D; Humphrey, Linda L.; Nygren, Peggy; Teutsch, Steven M.; Allan, Janet D.

doi:10.1001/jama.288.7.872

Cited by 923 publications

(569 citation statements)

References 147 publications

(216 reference statements)

Supporting

Mentioning

510

Contrasting

Unclassified

Order By: Relevance

“…Firstly, women who take HRT have access to health care, thus have a greater likelihood of being treated for co-morbidity or being motivated to undergo mammographic screening [27]. However, in the province of Limburg, the reduction in HRT use was not followed by a decrease in mammographic screening, in contrary the screening rose in that period.…”

Section: Discussionmentioning

confidence: 99%

Reduction in hormone replacement therapy use and declining breast cancer incidence in the Belgian province of Limburg

Vankrunkelsven

Kellen

Lousbergh

et al. 2009

Breast Cancer Res Treat

View full text Add to dashboard Cite

Breast cancer is the most common female cancer in Europe, but its incidence and mortality are rapidly changing across Europe. The early termination of the women's health initiative (WHI) trial, after the detection of an increased breast cancer risk in hormone replacement therapy (HRT) users, was followed by strong declines of HRT use worldwide. We investigated whether the reduction of HRT sales affected breast cancer incidence in the Belgian province Limburg. All women registered in the Limburg Cancer Registry with a diagnosis of invasive breast cancer diagnosed between 1/1/1996 and 31/12/2005 were included in the study. Data on the use of HRT in the population were obtained from the vendors and the social security system. For age-standardization using the direct method, the European standard population was taken. In 2003 and 2004, the breast cancer incidence rate decreased significantly as compared to 2002 for women aged between 50 and 69 years. This sudden drop in the incidence intercepted a markedly increasing trend until 2002, but was followed again by an increase in 2005. Between 2002 and 2006, the sales of HRT (about 75% to women aged 50-69 years) were reduced by 41%. Breast cancer incidence was maximally related to HRT use in the previous year (R 2 = 77%). The decrease of breast cancer incidence in the Belgian province of Limburg may largely be related to the fall of HRT use following the early termination of the WHI trial. This suggests that HRT stimulates the growth of preexisting, clinically latent tumours that may not otherwise become clinically apparent.

show abstract

Section: Discussionmentioning

confidence: 99%

Reduction in hormone replacement therapy use and declining breast cancer incidence in the Belgian province of Limburg

Vankrunkelsven

Kellen

Lousbergh

et al. 2009

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…The relation between HRT and gastric adenocarcinoma warrants further research before any clinical implications would be appropriate, particularly given the initial enthusiasm about the seemingly protective effect of HRT against cardiovascular disease, which was later not supported (Nelson et al, 2002).…”

Section: Discussionmentioning

confidence: 99%

Hormone replacement therapy and risks of oesophageal and gastric adenocarcinomas

et al. 2005

View full text Add to dashboard Cite

Oesophageal and gastric adenocarcinoma share an unexplained male predominance, which would be explained by the hypothesis that oestrogens are protective in this respect. We carried out a nested case -control study of hormone replacement therapy (HRT) among 299 women with oesophageal cancer, 313 with gastric cancer, and 3191 randomly selected control women, frequency matched by age and calendar year in the General Practitioners Research Database in the United Kingdom. Data were adjusted for age, calendar year, tobacco smoking, alcohol consumption, body mass index, hysterectomy, and upper gastrointestinal disorders. Among 1 619 563 person-years of follow-up, more than 50% reduced risk of gastric adenocarcinoma was found among users of HRT compared to nonusers (odds ratio (OR), 0.48, 95% confidence interval (CI) 0.29 -0.79). This inverse association appeared to be stronger for gastric noncardia (OR 0.34, 95% CI 0.14 -0.78) and weaker for gastric cardia tumours (OR 0.68, 95% CI 0.23 -2.01). There was no association between HRT and oesophageal adenocarcinoma (OR 1.17, 95% CI 0.41 -3.32).

show abstract

“…[10]. Le choix de cette réfé-rence a été motivé par la nature de cette publication : scientific review et par l'absence de données propres à la situation française.…”

Section: Sud-est 35unclassified

Méthodologie de l’enquête MISSION (Ménopause, rISque de cancer du SeIn, mOrbidité et prévaleNce)

Chevallier¹,

Daurès²,

Micheletti³

et al. 2005

Journal de Gynécologie Obstétrique et Biologie de la Reproducti

View full text Add to dashboard Cite

Postmenopausal Hormone Replacement Therapy

Cited by 923 publications

References 147 publications

Reduction in hormone replacement therapy use and declining breast cancer incidence in the Belgian province of Limburg

Reduction in hormone replacement therapy use and declining breast cancer incidence in the Belgian province of Limburg

Hormone replacement therapy and risks of oesophageal and gastric adenocarcinomas

Méthodologie de l’enquête MISSION (Ménopause, rISque de cancer du SeIn, mOrbidité et prévaleNce)

Contact Info

Product

Resources

About